Women's perspectives on the acceptability and feasibility of an HPV screen-and-treat approach to cervical cancer prevention in Iquitos, Peru: a qualitative study.
Ablative therapy
Acceptability
Cervical cancer
Screen-and-treat
Thermal ablation
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
10 10 2022
10 10 2022
Historique:
received:
13
05
2022
accepted:
22
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
13
10
2022
Statut:
epublish
Résumé
The objective of this study was to explore women's experiences of a screen-and-treat approach with ablative therapy (referred to by the Spanish acronym TVT-TA) as a method of treatment following a positive HPV test in Iquitos, Peru. A total of 111 in-depth interviews were conducted with 47 HPV positive women who attended the TVT-TA procedure at a primary-level healthcare facility. Interviews were conducted immediately before, immediately after, and six-weeks after TVT-TA. Most interviewed women reported experiencing moderate pain during ablative therapy and minimal pain immediately after and six weeks after ablative therapy. Women also stated that the pain was less intense than they had expected. The most common physical after-effects of treatment were bleeding and vaginal odor. Women experienced oscillating emotions with fear upon receiving a positive HPV result, calming after hearing about ablative therapy treatment, worry about pain from the treatment itself, relaxation with counseling about the procedure, and relief following treatment. Nearly all participants emphasized that they were pleased with the TVT-TA process even if they had experienced pain during TVT-TA, recommended that TVT-TA be expanded and available to more women, and stated that TVT-TA was faster and easier than expected. This study found that TVT-TA is a feasible and acceptable means of treating HPV according to the women receiving the treatment.
Sections du résumé
BACKGROUND
The objective of this study was to explore women's experiences of a screen-and-treat approach with ablative therapy (referred to by the Spanish acronym TVT-TA) as a method of treatment following a positive HPV test in Iquitos, Peru.
METHODS
A total of 111 in-depth interviews were conducted with 47 HPV positive women who attended the TVT-TA procedure at a primary-level healthcare facility. Interviews were conducted immediately before, immediately after, and six-weeks after TVT-TA.
RESULTS
Most interviewed women reported experiencing moderate pain during ablative therapy and minimal pain immediately after and six weeks after ablative therapy. Women also stated that the pain was less intense than they had expected. The most common physical after-effects of treatment were bleeding and vaginal odor. Women experienced oscillating emotions with fear upon receiving a positive HPV result, calming after hearing about ablative therapy treatment, worry about pain from the treatment itself, relaxation with counseling about the procedure, and relief following treatment.
CONCLUSIONS
Nearly all participants emphasized that they were pleased with the TVT-TA process even if they had experienced pain during TVT-TA, recommended that TVT-TA be expanded and available to more women, and stated that TVT-TA was faster and easier than expected. This study found that TVT-TA is a feasible and acceptable means of treating HPV according to the women receiving the treatment.
Identifiants
pubmed: 36217187
doi: 10.1186/s12905-022-01943-3
pii: 10.1186/s12905-022-01943-3
pmc: PMC9552409
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
414Subventions
Organisme : FIC NIH HHS
ID : D43 TW009345
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190366
Pays : United States
Investigateurs
Meda Del Carpio-Morgan
(M)
Esther Y Garcia Satalay
(EY)
Sarah D Gilman
(SD)
José Jerónimo
(J)
Alcedo Jorges
(A)
Magdalena Jurczuk
(M)
Margaret Kosek
(M)
Gabriela Ladrón de Guevarra
(G)
Renso Lopez Liñán
(R)
Andrea Matos Orbegozo
(A)
Jaime Marín
(J)
Graciela Meza
(G)
Reyles Ríos Reátegui
(R)
Karina Román
(K)
Anne F Rositch
(AF)
Nolberto Tangoa
(N)
Javier Vásquez Vásquez
(J)
Giannina Vásquez Del Aguila
(G)
Karen Zevallos
(K)
Informations de copyright
© 2022. The Author(s).
Références
Curr Probl Cancer. 2018 Mar - Apr;42(2):129-136
pubmed: 29428790
BMC Cancer. 2019 Apr 23;19(1):367
pubmed: 31014287
Salud Colect. 2012 Dec;8(3):247-261
pubmed: 23681458
BMC Womens Health. 2017 Jan 7;17(1):2
pubmed: 28061842
Int J Gynaecol Obstet. 2016 Jun;133(3):351-4
pubmed: 27005927
Prev Med. 2019 Jan;118:81-91
pubmed: 30342109
JAMA. 2012 Feb 8;307(6):565-6
pubmed: 22318274
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Lancet Glob Health. 2019 May;7(5):e556-e557
pubmed: 31000123
Cancer Detect Prev. 2003;27(6):466-71
pubmed: 14642555
Lancet Glob Health. 2015 Feb;3(2):e85-94
pubmed: 25617202
J Low Genit Tract Dis. 2017 Jan;21(1):26-32
pubmed: 27922905
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1710-1719
pubmed: 32561563
Int J Gynaecol Obstet. 2022 Apr;157(1):85-89
pubmed: 34197624
BMC Cancer. 2021 Apr 22;21(1):428
pubmed: 33882885
Rev Salud Publica (Bogota). 2010 Feb;12(1):1-13
pubmed: 20628695
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Int J Cancer. 2020 Sep 1;147(5):1275-1285
pubmed: 31970767
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310